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rule-fixed algorithm, by thoroughly reviewing and scoring, chapter 
by chapter, the recent publications for their scientific validity (Ox-
ford level of evidence and grades of recommendation (LoE, GR)) 
[1] and clinical relevance (AGO recommendation (AGO); supple-
mentary table 1). We present the 2018 update; the full version of 
the updated slide set is available online as a portable document for-
mat (PDF) file in both English and German [2].
Options for Primary Prevention: Modifiable  
Lifestyle Factors
Individual risk factors can be classified into non-modifiable, 
modifiable, and socially defined factors. Currently, there is good 
evidence that changes in some modifiable risk factors could sub-
stantially decrease the individual breast cancer risk.
Relevant lifestyle factors such as obesity, alcohol consumption, 
physical inactivity, smoking, and low fiber intake are well known. 
Furthermore, there is new data from a Dutch retrospective cohort 
study confirming that 25.7% of postmenopausal breast cancer cases 
are associated with lifestyle factors [3].
We would like to stress that obesity (high body mass index 
(BMI)) has a particularly significant influence on the incidence of 
primary and recurrent breast cancer. There is, however, uncer-
tainty as to whether a high BMI is significantly associated with the 
diagnosis of triple-negative breast cancer (TNBC) [4]. Changing 
one’s lifestyle has a preventive effect with regard to breast cancer: 
Maintenance of normal weight, fat-reduced diets, reductions in 
meat consumption and alcohol intake (particularly in case of estro-
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Introduction
For almost 20 years, the Breast Committee of the Arbeitsge-
meinschaft Gynäkologische Onkologie (German Gynecological 
Oncology Group/AGO) has been preparing and updating evi-
dence-based recommendations for the diagnosis and treatment of 
patients with early and metastatic breast cancer. The AGO Breast 
Committee consists of gynecological oncologists specialized in 
breast cancer and interdisciplinary members specialized in pathol-
ogy, radiological diagnostics, medical oncology, and radiation on-
cology. This update was performed according to a documented 
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gen and progesterone receptor(ER/PR)-positive and/or invasive 
lobular tumors), smoking cessation, physical exercise, and avoid-
ance of hormonal therapy (especially estrogen/progestin combina-
tion regimens) in postmenopausal women are controllable factors 
that may reduce the breast cancer risk.
Breast Cancer Risk and Prevention
Mutation analyses of BRCA1, BRCA2 and possibly other genes 
are currently being carried out on people with a family history of 
breast and ovarian cancer. A checklist facilitates the identification 
of persons with familial criteria for whom genetic counseling is an 
option. In addition, testing should be performed in the context of a 
therapeutic option (e.g., a poly(ADP-ribose) polymerase (PARP) 
inhibitor) as a consequence of data on the use of PARP inhibitors 
in BRCA1/2 mutation carriers with advanced breast cancer [5]. 
Current data suggest that genes other than BRCA1 and BRCA2, 
which are real high-risk breast cancer susceptibility genes (LoE 
2a/1b/A/AGO++), are also associated with high risk of developing 
breast cancer [6]. However, before the widespread use of preven-
tive measures, their effectiveness must be proven. Moreover, there 
are many non-BRCA-associated hereditary cancer syndromes with 
an increased risk for breast cancer (Li-Fraumeni syndrome, 
Cowden syndrome, hereditary diffuse gastric cancer syndrome, 
Peutz-Jeghers syndrome, Lynch syndrome). The penetrance of 
these genes depends on the family cancer history and the individ-
ual cancer load. The use of commercially available but not vali-
dated breast cancer gene panels for risk prediction is not recom-
mended outside of prospective studies (LoE 3a/B/AGO+/–). Fur-
thermore, clinical genetic testing for low-risk variants in clinical 
routine should be avoided (LoE 3b/D/AGO–). For many of these 
genetically defined subtypes, issues such as histopathological fea-
tures, sensitivity to different screening modalities, course of dis-
ease, or specific treatment response still remain unclear.
In the context of gene panel testing, 20–30% of genetic test results 
reveal variants of unknown significance (VUS). Applying the classi-
fication of the International Agency for Research on Cancer (IARC), 
VUS are class 3 aberrations with a probability of being deleterious in 
5–95% of cases [7]. Only class 4 and 5 variants (probability of >95% 
and >99%, respectively) are clinically relevant. As more than 60% of 
the class 3 variants are extremely rare and population specific, only 
large databases such as that of the German Consortium of Heredi-
tary Breast and Ovarian Cancer (GC-HBOC) or ENIGMA allow fur-
ther classification of most of these variants and their publication in 
also publicly accessible databases such as clinvar.
Women with BRCA1/2 mutations should be offered nondirec-
tive counseling for the uptake of primary preventive measures (e.g., 
risk-reducing bilateral salpingo-oophorectomy after completion of 
family planning (LoE 2c/B/AGO++), risk-reducing bilateral mas-
tectomy (LoE 2c/B/AGO+), or medical prevention with tamoxifen 
(LoE 1a/A/AGO+), raloxifen (LoE 1b/A/AGO+), or an aromatase 
inhibitor (AI) (LoE 1b/A/AGO+)) in addition to participation in an 
intensified surveillance program. Risk-reducing bilateral mastec-
tomy after ovarian cancer is predominantly not indicated and could 
be thoroughly discussed depending on tumor stage (International 
Federation of Gynecology and Obstetrics (FIGO) I/II), recurrence-
free time (˰5 years) and age (<55 years) (LoE 4/C/AGO+/–). How-
ever, uni- or bilateral mastectomy is not indicated in the absence of 
clearly defined genetic risk factors (LoE 2a/B/AGO+).
Data regarding the clinical benefit of risk-reducing contralateral 
mastectomy in affected BRCA1/2 mutation carriers suggested a 
disease-free survival (DFS) and overall survival (OS) benefit in spe-
cific subgroups only, particularly in patients aged <40 years with 
grade 1/2 (G1/2) tumors, no TNBC, and no chemotherapy. There-
fore, this intervention has to be thoroughly discussed with each in-
dividual patient (LoE 2b/B/AGO+/–). Breast-conserving therapy 
(BCT) is safe (LoE 2a/B/AGO+) and systemic therapy can be given 
according to recommendations for sporadic breast cancer (LoE 
3a/B/AGO+). The addition of carboplatin to neoadjuvant chemo-
therapy (NACT) seems to be beneficial for patients with TNBC re-
gardless of their BRCA1 or BRCA2 mutation status [8]. Overall, 
the TNBC status in association with a BRCA1 or BRCA2 mutation 
displays an even higher overall chemotherapy sensitivity and better 
clinical outcome in comparison to patients without a BRCA1 or 
BRCA2 mutation.
To date, for the first time, there are treatment recommendations 
specific to BRCA1/2 mutation carriers in the metastatic stage of 
their breast cancer. Based on data from the OlympiaD trial [9], 
PARP inhibitor monotherapy significantly prolongs the progres-
sion-free survival (PFS) in human epidermal growth factor recep-
tor 2(HER2)-negative metastatic breast cancer patients with ger-
mline BRCA1/2 mutation compared to standard therapy (LoE 
1b/A/AGO+). Moreover, in the advanced disease stage, carboplatin 
represents an effective treatment option favored over docetaxel in 
patients with breast cancer carrying a BRCA mutation (LoE 2b/B/
AGO+).
Breast Cancer Diagnostics
The aim of early detection and screening of breast cancer is to 
reduce breast cancer-specific mortality and treatment-dependent 
morbidity. Professionals and women need to be informed about 
the benefits and harms of cancer screening tests before making 
medical decisions. This includes clear and understandable infor-
mation in absolute terms about false-positive rates (FPRs), false-
negative rates (FNRs), overdiagnosis, and overtreatment.
All available evidence confirms that mammography screening is 
capable of significantly reducing breast cancer mortality [10]. 
Based on a review by Oeffinger et al. [11], the number needed to 
screen (NNS) to prevent 1 breast cancer death with a mortality re-
duction of 20% (40%) was estimated for women aged 40–49 years 
to be 1,770 (753), for women aged 50–59 years 1,087 (462), and for 
women aged 60–69 years 835 (355). Screening mammography for 
breast cancer is recommended for women 50–74 years of age (LoE 
1a/A/AGO++) [12–18]. For women 40–49 years of age, individual 
shared decision-making is recommended as these women would 
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have smaller beneficial health effects than women of older age 
groups, e.g., higher recall rates for additional imaging and biopsy 
rates (LoE 1a/B/AGO+) [19–21]. There are no studies on women 
older than 75 years of age. However, in view of an aging popula-
tion, screening can be offered to women in good health with a life 
expectancy of 10 years or longer (LoE 4/C/AGO+).
For breast cancer screening, neither hand-held ultrasound 
(HHUS) nor automated whole-breast ultrasound (ABUS) alone are 
recommended (LoE 3a/C/AGO–). The arguments against ultra-
sound alone as a screening modality are lack of reproducibility, 
high FNR, low positive predictive value for biopsy, and lack of 
quality assurance.
The limitations of mammography are well known; hence, new 
technologies to overcome these constraints are highly welcome. 
Beside retrospective studies, 4 prospective studies within the Euro-
pean Breast Cancer Screening Program and 3 systematic reviews 
have been published. Digital breast tomosynthesis (DBT) added to 
2-dimensional (2D) mammography proved to significantly in-
crease the invasive cancer detection rate and reduced false-positive 
outcomes. In addition, first results on interval cancer rates showed 
a decrease. However, the radiation dose received with dual acquisi-
tion is increased [22–27].
DBT is particularly recommended if further mammographic di-
agnostic interventions like digital spot compression view are re-
quested [28, 29] (LoE 2b/B/AGO+).
Mammography has a lower sensitivity and specificity in women 
with increased breast density, who also have a higher risk of breast 
cancer. To describe the mammographic breast composition, the 
detectability of masses affected by breast density (A–D) is recom-
mended instead of the former categories using the percentage of 
glandular tissue (1–4) [30, 31]. However, there is no gold standard 
for density determination as accuracy studies are missing. The re-
cent (2016) systematic review by Melnikow et al. [32] revealed a 
reclassification rate of 12.6–18.7%. The use of adjunct imaging 
techniques (DBT, HHUS, ABUS, magnetic resonance imaging 
(MRI)) in women with dense breast tissue increased the detection 
rate of cancers (rather than of ductal carcinoma in situ (DCIS)) for 
all imaging modalities. Harmful effects of supplemental imaging in 
women with dense breasts included higher recall and biopsy rates 
for women who do not have breast cancer. With DBT, the recall 
and biopsy rates were low (LoE 2b/B/AGO+). Considering recent 
results of observational studies, HHUS struck the best balance on 
benefits and harms [33, 34] (LoE 3b/B/AGO+).
To assess breast symptoms or lesions, clinical examination (LoE 
3b/B/AGO++), mammography (LoE 1b/A/AGO++), DBT where 
available (LoE 2b/B/AGO+), ultrasound (LoE 2b/B/AGO++), and 
minimal invasive biopsies (LoE 1c/A/AGO++) should be per-
formed. Elastography (LoE 2b/B/AGO+) serves as an adjunct diag-
nostic modality and shows potential to decrease the false-positive 
biopsy rate.
Contrast-enhanced MRI plays an important role in acknowl-
edged indications in diagnostic breast imaging as well as in high-
risk patients. MRI should not be generally used to assess symptoms 
or breast lesions. MRI can be used if clinical examination, mam-
mography, ultrasound and needle biopsy do not allow a definitive 
diagnosis (LoE 3b/B/AGO+). Second-look ultrasound is recom-
mended in the case of lesions detected by MRI alone.
MRI should not be used in general for preoperative staging pur-
poses in the case of BCT. According to a meta-analysis, the re-exci-
sion rate was not reduced. Furthermore, the initial and total rates 
of mastectomy increased if a preoperative breast MRI was per-
formed compared with no preoperative breast MRI [35, 36]. Pre-
operative breast MRI did neither help to reduce the rate of local 
recurrences nor to improve the local recurrence-free survival or 
distant metastasis-free survival [37]. It is important to realize that 
MRI-detected suspicious lesions should prompt MRI-based biopsy 
or marking for clarification. For some patients, e.g. those with re-
duced lesion detectability in mammography and ultrasound (de-
tectability C–D), nipple involvement, lobular invasive cancer, sus-
picion of multilocular disease, and high risk, MRI can be consid-
ered (LoE 1b/B/AGO+/–) [38, 39]. The performance of MRI-
guided vacuum-assisted biopsies is mandatory if suspicious lesions 
are detected by MRI of the breast.
In the case of clinical and/or sonographic suspicious axillary 
lymph nodes, core needle biopsy is recommended to detect exten-
sive axillary disease (LoE 2b/B/AGO++). Tagging the biopsied 
node with a titan clip may be helpful to identify it later; however, 
there is no agreement on the ideal technique (LoE 3b C/AGO+/–) 
and study participation is recommended. The standard procedure 
in patients with clinically negative axillary lymph nodes is sentinel 
lymph node biopsy (SLNB).
Imaging for metastasis is recommended with computed tomog-
raphy (CT) scan thorax/abdomen and bone scan in patients with 
high risk of metastasis (e.g. lymph node positivity) and/or symp-
toms, or if (neo-)adjuvant chemotherapy and/or HER2 treatment 
is indicated (LoE 2b/B/AGO+) [40].
Pathology
Little has changed with regard to routine pathological manage-
ment of breast cancer.
When determining the ER status, it is recommended to recog-
nize cancers with low receptor expression (>1–10%) as a biologi-
cally distinct group. Breast cancers with borderline hormone re-
ceptor (HR) expression (>1 to <10%) were initially regarded as 
HR-negative; however, today they are classified as HR-positive due 
to a change in the American Society of Clinical Oncology (ASCO)/
College of American Pathologists (CAP) guidelines. It has to be ac-
knowledged though that the majority of data supporting this was 
published at a time when immunohistochemistry was not as stand-
ardized and sensitive as it is today. In contrast, recent publications 
[41–44] suggest that tumors with low ER expression share several 
features with TNBC, such as BRCAness, gene expression profiles, 
and prognosis. Therefore, it is recommended to define these can-
cers as ‘low positive’ rather than ‘positive’ in histology reporting. 
Nevertheless, the clinical consequences of this differentiation re-
main unclear.
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Lesions of Uncertain Malignant Potential (B3)
The group of lesions of uncertain malignant potential (B3) are 
typically detected in core or vacuum-assisted biopsy in asympto-
matic women. The risk that is associated with B3 lesions cannot 
be strictly categorized according to the type of lesion (atypical 
ductal hyperplasia (ADH), flat epithelial atypia (FEA), lobular in-
traepithelial neoplasia (LIN), papilloma, radial scar), but addi-
tional clinical and pathological factors must be taken into consid-
eration. The aim of further excision of B3 lesions is to detect more 
severe lesions, such as DCIS, which may be associated with a 
given B3 lesion, but also to minimize the risk of progression of a 
lesion of low malignant potential to an in situ carcinoma or inva-
sive carcinoma [45].
ADH is characterized by a low-grade, monomorphic prolifera-
tion of atypical ductal epithelial cells which either partially or com-
pletely involve terminal ductal spaces but involve the ductal spaces 
to a total extent of less than 2 mm [46]. In a recent study on the 
long-term outcome of patients with ADH or lobular carcinoma in 
situ (LCIS) who underwent immediate re-excision after diagnosis 
on core needle biopsy, 30% of women had carcinoma or DCIS after 
the diagnosis of ADH, and an additional 8% of these women subse-
quently developed carcinoma with a mean follow-up of 76 months. 
Women who had a benign immediate re-excision had a similar rate 
of 11.5% [47]. A somewhat lower rate of invasive carcinomas after 
follow-up of ADH after excisional biopsy was reported in historic 
data sets [48]. The reason for the high upgrade rate on open biopsy 
after the diagnosis of ADH is believed to be that ADH on core bi-
opsy not infrequently represents inadequately sampled DCIS. In 
the same study, approximately three-quarters of the reported inva-
sive carcinomas and DCIS after the diagnosis of ADH and a subse-
quent benign open biopsy occurred in the same breast.
The role of lobular neoplasia (LN) as a precursor lesion for in-
vasive lobular carcinoma has been confirmed recently [49]. How-
ever, because of the low-risk nature of classical LN, a consensus has 
been reached that open excision can be avoided after the diagnosis 
of classical LN was established on core biopsy, and no discordant 
imaging, especially no focal lesion, is present [50, 51]. This is sup-
ported by recent clinical data [52]. In contrast, high-risk variants of 
LN, which include pleomorphic and florid LCIS (pLCIS and fLCIS) 
are recommended for open biopsy, and preferably complete exci-
sion. Therefore, the pathologic distinction of classical-type LN 
from high-risk variants on core biopsy is most important [53].
A similar approach of conservative management avoiding open 
biopsy in the typical case of FEA has been recommended, provided 
that no mass lesion is present and imaging findings are concordant 
with pathologic findings [54]. An increased risk, and consequently 
a possible indication, has been suggested in cases of residual micro-
calcifications or with pure, prominent FEA following core biopsy 
[55, 56]. Therefore, careful imaging-pathology correlation is rec-
ommended when considering treatment options in FEA [57].
The diagnosis of solitary or multiple papillomas on core biopsy 
carries a risk of approximately 10% for an invasive carcinoma or 
DCIS [58]. However, upgrade rates are widely different in the liter-
ature and may be as low as 3.1% [59]. It is important to distinguish 
papillomas that are associated with mass lesions from peripheral 
papillomas, which are often smaller but are commonly associated 
with proliferative breast disease. Clinical factors and imaging risk 
factors that are associated with increased risk include patient age, 
lesion multiplicity, and peripheral location. Significant risk factors 
on mammography include visibility and density, and on ultra-
sound, echo patterns, boundary and vascularity [60]. When papil-
lomas were removed by vacuum-assisted core biopsies, no invasive 
cancer was seen on follow-up after 3.5 years. Therefore, conserva-
tive management is justified provided that the biopsy has been suf-
ficiently representative and no discordance to imaging results was 
evident [61, 62].
A radial sclerosing lesion or radial scar may mimic carcinoma 
mammographically because of its stellate appearance. Radial scle-
rosing lesions are only rarely associated with atypia or DCIS [63]. 
Therefore, radial scars most often are benign lesions, and recent 
studies with careful radiological correlation have indicated that 
open biopsy may not be necessary for small lesions and for com-
plete removal of the imaging abnormality [64–66].
In summary, there is accumulating evidence that open biopsy 
may be necessary only for a subset of patients with FEA, LIN, pap-
illoma, or radial scar lesions, provided that careful radiologic-path-
ologic correlation was performed, no clinical, imaging, or patho-
logic high-risk factors are present, and that the imaging abnormal-
ity was completely or at least sufficiently representatively removed. 
This can often be achieved with a diagnostic-therapeutic vacuum-
assisted biopsy [67]. ADH is an exception and should be excised on 
most instances.
Ductal Carcinoma in situ
The diagnosis of DCIS increased dramatically following the in-
troduction of screening mammography and comprises approxi-
mately >20% of all newly diagnosed breast cancers [68]. However, 
epidemiological studies demonstrate that the removal of DCIS le-
sions has not been accompanied by a reduction in the incidence of 
invasive breast cancer [69, 70]. The challenge of DCIS is to mini-
mize the risk of overdiagnosis, to avoid under- or overtreatment 
and to prevent the development of invasive breast cancer. DCIS is 
commonly diagnosed by mammography, but up to 20% of DCIS 
remain mammographically occult due to the lack of calcifications 
and/or small tumor dimensions. The use of additional imaging 
techniques may theoretically be helpful to detect the full extent of a 
lesion and define surgical treatment. However, for the time being, 
the role of MRI in DCIS is limited. Breast MRI has a high sensitiv-
ity in the diagnosis of invasive breast cancer, varying from 90 to 
100%. The sensitivity for the diagnosis of DCIS is 77–96% [71]. In 
summary, MRI does not improve the results of surgical therapy of 
DCIS [72, 73].
The biological characteristics of DCIS often predict recurrence 
and the type of invasive cancer that may develop in the future. 
Among patients with DCIS, the breast cancer-specific mortality 
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was associated with age at diagnosis, ethnicity, grade, size, and ER 
status [74]. With appropriate risk prediction of subsequent devel-
opment of invasive cancer, there is a better chance for individual-
ized therapy. Breast cancer surgery (BCS) aims at the complete re-
moval of the DCIS and represents the more favorable treatment in 
a majority of patients. Negative margins of at least 2 mm are asso-
ciated with a reduced risk of ipsilateral breast tumor recurrence 
(IBTR) compared with positive margins defined as ink on DCIS. 
Negative margins of less than 2 mm alone are not an indication for 
mastectomy, and factors known to impact rates of IBTR should be 
considered in determining the need for re-excision [75, 76]. The 
majority of trials reveal that, after surgery, adjuvant treatments re-
duce the rate of recurrent DCIS, and invasive recurrences have at 
the same time been unable to show an effect on mortality. Radio-
therapy after BCS has been shown to halve both, in situ and inva-
sive recurrences, in 5 phase III trials, 2 of which have also demon-
strated that tamoxifen 20 mg/day reduces the risk of ipsilateral and 
contralateral events by approximately 30% at both 10 and 15 years 
(LoE 1a/A/AGO+) [77, 78]. Omitting radiotherapy implies an ele-
vated risk for local recurrence without an effect on OS even in the 
subset of ‘good-risk’ lesions. There remains a lack of level-1 evi-
dence supporting the omission of adjuvant radiotherapy in selected 
low-risk cases such as those with tumors < 2.5 cm, low and inter-
mediate nuclear grade, and mammographically detected DCIS. 
Retrospective evaluation of the ER status showed that tamoxifen 
reduced any subsequent breast events by 42% in ER-positive DCIS 
[79, 80]. AIs offer another endocrine option for postmenopausal 
women with ER-positive DCIS, and the choice between an AI and 
tamoxifen will probably depend more on the previous history of 
other conditions (e.g. osteoporosis and venous thrombosis) and 
short-term tolerability than on differences in efficacy. OS is not im-
proved by endocrine therapy.
The optimal management in particular of adjuvant treatment 
and long-term risks must be discussed with the patients. Hence, 
the potential side effects of radiation therapy and endocrine ther-
apy, albeit small, must be weighed more carefully when making 
treatment decisions for patients with DCIS.
Prognostic and Predictive Factors
Prognostic and predictive factors are an essential part of therapy 
concepts in early and advanced breast cancer. In 2018, the AGO 
guidelines for prognostic and predictive factors did not change 
substantially, since the data presented in 2017 altered the evidence 
levels (LoE) but not the AGO recommendations.
In HR-positive HER2-negative early breast cancer with 0–3 in-
volved lymph nodes, gene expression assays may be used if estab-
lished clinical pathological factors do not allow therapy decisions 
regarding the use of chemotherapy in addition to the standard of 
endocrine therapy. Patients with an estimated risk of recurrence of 
more than 10% at 10 years are generally considered candidates for 
upfront or adjuvant chemotherapy. The AGO recommends 4 tests 
(AGO+) that have been thoroughly validated retrospectively (LoE 
IB for Endopredict®, Prosigna®) and prospectively (LoE IA for 
MammaPrint®, Oncotype DX®) for use in clinical routine. Pro-
spective 5-year outcome data for Oncotype DX from the West Ger-
man Study Group (WSG) PlanB trial [81] and for MammaPrint 
from the MINDACT trial [82] confirmed an excellent outcome in 
pN0–1 patients who had low-risk test results. Clinical outcome 
data from an analysis of a large prospectively designed registry in-
vestigating patients over a longer period confirm these results in 
real-life clinical practice [83]. Apart from the gene expression pro-
files, the tumor tissue concentrations of uPA/PAI1 (FEMTELLE®) 
still have the highest levels of evidence (LoE 1aA/AGO+) with re-
gard to identification of those patients with node-negative breast 
cancer who can avoid adjuvant chemotherapy for having a very 
low risk for recurrence. Moreover, pooled data suggests that high 
levels of these markers may predict benefit from chemotherapy 
[199, 200].
In HER2-positive early breast cancer, a meta-analysis (n = 967) 
demonstrates that pathological complete response (pCR) after neo-
adjuvant therapy (chemotherapy + anti-HER2 therapy) is signifi-
cantly lower in phosphatidylinositol-4,5-bisphosphate 3-kinase 
catalytic subunit alpha (PIK3CA)-mutant versus wild-type tumors 
(16.2% vs. 29.6%; p < 0.001) (LoE IB). This difference was mostly 
due to a substantial difference in HR-positive tumors with pCR 
rates of 7.6% versus 24.2% (p < 0.001); in HR-negative tumors, the 
numerical difference was not significant (27.2 vs. 36.4%; p = 0.125) 
[84]. Due to the lack of clinical consequences, there is no AGO rec-
ommendation for PIK3CA mutation analysis before NACT, so far 
(AGO +/–).
In triple-negative early breast cancer, the germline BRCA status 
is predictive in response to NACT. In the neoadjuvant Gepar-
Quinto trial, in 74 (15.8%) out of 469 TNBC patients with available 
germline DNA, BRCA1 (n = 61) or BRCA2 (n = 13) mutations 
were detected. pCR (ypT0/ypN0) was observed in 50% (n = 37) of 
the mutation carriers, but in only 31.1% (n = 123) of the patients 
without mutations (p = 0.002). In patients without BRCA muta-
tions (hazard ratio (HR) = 0.20; 95% confidence interval (CI) 0.11–
0.34; p < 0.001) but not in mutation carriers (HR = 0.48; 95% CI 
0.18–1.27; p = 0.129), pCR (ypT0/ypN0) was significantly corre-
lated with DFS [85].
As there are evidence-based consequences for patient manage-
ment beyond the neoadjuvant therapy, germline BRCA determina-
tion is recommended in TNBC (LoE IIB AGO+). Yet, as shown 
earlier in the GeparSixto trial, the use of platinum should not de-
pend on the germline BRCA status.
In patients with NACT, detection of ˰1 circulating tumor cell 
(CTC) is an independent prognostic factor for locoregional re-
lapse-free survival (HR = 1.8; CI 1.2–2.7; p = 0.001), distant DFS 
(HR = 2.4; CI 1.9–3.1; p < 0.0001), and OS (HR = 2.6; CI 1.9–3.4; p 
< 0.0001). CTC positivity was not correlated with pCR in this 
meta-analysis comprising 2,156 patients from 21 studies [86]. De-
spite the high level of evidence (LoE Ia/B), the AGO does not rec-
ommend CTC detection in clinical routine due to the lack of thera-
peutic consequences (AGO+/–).
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Breast Cancer Surgery under Oncological Aspects
The extent of breast surgery has been consistently reduced in 
recent years. No ink on tumor is the accepted standard for resec-
tion margins for patients who undergo primary surgery or surgery 
after NACT (provided that all suspicious lesions according to pre-
operative imaging are resected (LoE 2a/A/AGO++ and LoE 2b/B/
AGO++, respectively)).
Although the role of axillary dissection (AD) is still under de-
bate, especially in subsets of patients with clear indication for the 
adjuvant systemic treatment which is already defined by the intrin-
sic subtype of the tumor, the AGO clearly states that SLNB remains 
the standard of axillary staging for patients with invasive disease 
(LoE 1b/A/AGO++). AD as a staging procedure has already been 
deleted in the 2017 guidelines (LoE 3/A/AGO–). In patients with 
1–2 positive sentinel lymph nodes (SLNs) undergoing breast-con-
serving surgery as well as adequate systemic treatment and irradia-
tion of the breast, completion of axillary lymph node dissection 
(ALND) is omitted in clinical practice. The American College of 
Surgeons Oncology Group (ACOSOG) Z0011 trial presented 10-
year follow-up data in 2016 with no differences in locoregional re-
currences, DFS, and OS.
Due to limitations of the ACOSOG Z0011 trial and the lack of 
conformational studies, the AGO did not change the recommenda-
tion grade for AD in these patients (LoE 1b/B/AGO+/–) but rec-
ommends the participation in ongoing trials (e.g. INSEMA).
With regard to the technical aspects of the sentinel procedure, 
the role of presurgical lymphoscintigraphy (LSG) prior to SLNB 
was evaluated in a prospective multicentric randomized trial with 
1,200 patients. The surgeons were randomized to know or not to 
know the results of the LSG before starting the SLNB. The number 
of removed sentinel nodes and the number of positive or negative 
lymph nodes were identical in both groups. Therefore, time, cost, 
and presurgical procedures can be optimized without LSG [92] 
(LOE 1b (abstract) B/AGO+/–).
The role of SLNB in the neoadjuvant setting is still a matter 
of intense debate. Many clinicians agree that axillary staging after 
NACT would be more beneficial for the patient (reduction to 
one-step surgery, reduction of the AD rate due to conversion 
from cN+ to ycN0, determination of pCR as an important prog-
nostic parameter). However, data on the feasibility and reliability 
of SLNB in this setting were controversial, and data on regional 
recurrences are rare. The French GANEA II study, a prospective 
multicenter cohort study, enrolled 418 clinically node-negative 
patients who underwent SLNB alone after NACT. The detection 
rate for the SLN was 97%. Only 1 (0.2%) axillary recurrence 
was observed after 3 years. In a retrospective unicentric study, 
Galimberti et al. [201] published similar results. After 5 years of 
follow-up, only 1 (0.4%) axillary recurrence was observed in 249 
clinically node-negative patients who underwent SLNB after 
NACT. The AGO favors SLNB after NACT in cN0 patients (LoE 
2b/B/AGO+). SLNB before NACT remains an option if an im-
pact on adjuvant treatment decisions is expected (LoE 2b/B/
AGO+/–).
For patients who present initially with (histologically proven) 
positive axillary lymph nodes (pN+), the feasibility and accuracy of 
SLNB is lower than in the adjuvant setting (SENTINA, ACOSOG 
1071, GANEA I) [87–89]. Data on long-term outcome are insuffi-
cient, and it is unclear if the unfavorable FNRs translate into higher 
rates of recurrences. Therefore, the AGO still cannot generally rec-
ommend SLNB as standard procedure in clinically negative axillae 
after NACT (ycN0) in cases among whom tumor-infiltrated lymph 
nodes (cN+/pN+) have histologically been proven before NACT 
(LoE 2bB/AGO+/–). Instead, AD may be a safer alternative in such 
cases (LoE 2b/B/AGO+). Suggestions have been provided to im-
prove the FNR for patients who convert from cN+ to ycN0 after 
NACT. The 2018 AGO recommendations reviewed LoE for these 
candidates. An unplanned retrospective analysis of the ACOSOG 
Z1071 study revealed that the FNR could be improved when more 
than 2 SLNs were removed or when a dual tracer technique was ap-
plied. More than 2 SLNs were, however, identified in only 43.1% of 
the patients in the ACOSOG study and in 34% in the SENTINA 
trial. The recommendation of removing more than 2 SLNs would 
therefore be applicable in only an insufficiently small cohort of pa-
tients. It could furthermore motivate surgeons to remove addi-
tional non-SLNs and thus perform an undirected sampling (LoE 
3b/C/AGO+/–). The improvement of the FNR by use of a dual 
tracer technique was not confirmed in the multivariate analysis of 
the SENTINA trial. Patients with a dual tracer had significantly 
more lymph nodes removed (3 vs. 2). The FNR was not signifi-
cantly associated with the tracer technique (LoE 3b/C/AGO+/–). 
The prospective French FNAC study showed a significant correla-
tion between the size of the lymph node metastases (defined as 
pN+) and the FNR. When only patients with macrometastases 
were considered as pN+, the FNR was 16.9%. When micrometasta-
ses (pN+ (mi)) or isolated tumor cells (pN0 (i+)) were considered 
as positive, the FNR dropped to 13.3 and 8.4%, respectively [90] 
(LoE 2b/B/AGO+/–). Therefore, the recommendations regarding 
pathological ultrastaging have been updated in this setting (LoE 
2b/B/AGO+), especially with regard to ongoing treatments after 
NACT among patients without a pCR.
With the combined use of SLNB and a targeted removal of the 
biopsy-proven positive lymph node marked with a clip, seeds, or 
tattoo at the time of diagnosis (TAD = targeted axillary dissection), 
the FNR can potentially be reduced [91]. Many issues including the 
surgical technique, the reproducibility of this retrospective uni-
center study, and the extent of surgery are still unclear. Further 
studies (e.g. German SENTA, multicentric Tattoo) focusing on 
these issues are required before this procedure is introduced into 
routine clinical use (LoE 3b/C/AGO+/–). 
Oncoplastic and Reconstructive Surgery
Oncoplastic surgery today represents an essential component 
in the framework of an integrated treatment strategy for patients 
with breast carcinoma. It is defined as the use of plastic surgery 
techniques at the time of tumor removal, in order to achieve safe 
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resection margins, on the one hand, while on the other hand al-
lowing an aesthetic breast shape [93]. Oncoplastic surcery focuses 
on favorable scar positioning, adequate soft-tissue shaping, the 
choice of a suitable reconstruction procedure (particularly when 
radiotherapy is indicated), and reconstruction of the contralateral 
side in order to achieve symmetry. The basic principles of recon-
structive surgery (AGO++) require planning in an interdiscipli-
nary tumor board prior to the actual surgical procedure itself. In 
general, the least burdensome surgical technique with an aesthetic 
result that will be stable over the longer term should be selected. 
The patient must receive detailed information and advice about all 
surgical techniques and their advantages and disadvantages, and 
about the option of obtaining a second opinion. In case of an un-
favorable tumor/breast ratio, neoadjuvant systemic therapy might 
be considered, depending on the tumor biology. The preoperative 
counseling should include possible procedures for the contralat-
eral breast if indicated. Contralateral procedures and subsequent 
operations in order to achieve symmetry should therefore be dis-
cussed with the patient even before the first operation. These op-
erations are usually performed as secondary procedures after an 
interval of at least 3–6 months. The effects of radiotherapy on the 
affected side must be taken into account (e.g. volume reduction). 
Importantly, adjuvant therapy should not be delayed by breast 
reconstruction.
When mastectomy is necessary, skin-sparing techniques with 
complete resection of the breast tissue in suitably selected patients 
are associated with a similar recurrence rate and a better quality of 
life (LoE 2b/B/AGO++).
Depending on the location of the tumor, the mammillary and 
areola complex can also be preserved. The same also applies to pro-
phylactic mastectomy (LoE 2b/C/AGO+).
Following a mastectomy, reconstruction can be carried out 
using pedicled or free tissue transfer, and also with the use of sili-
cone gel-filled implants (LoE 2a/B/AGO+). A recent analysis in-
cluding 55,279 patients reported equal oncological safety compared 
to saline implants [94]. Reconstruction can be carried out either 
immediately or after an interval (LoE 3b/B/AGO++). The latter 
does not delay any necessary adjuvant therapies, but may result in 
shrinkage of the skin cover. When free tissue transfer is being used, 
the deep inferior epigastric perforator (DIEP) or free transverse 
rectus abdominis muscle (TRAM) flaps are available (LoE 2a/B/
AGO+). Both procedures are potentially muscle sparing, but the 
DIEP is associated with a lower rate of herniation.
In case of heterologous reconstruction, radiotherapy should be 
completed before using implants, to avoid a negative outcome 
(LoE 2a/B/AGO+) [95]. However, the patient must receive infor-
mation about a high complication rate (e.g., capsule contraction, 
revision operations, failure of the reconstruction, impaired cos-
metic appearance) and about the lower level of patient satisfaction 
in comparison with autologous reconstruction plus radiotherapy 
(LoE 2b/B) [96, 97].
In cases with indication for meshes, autologous tissue flaps (e.g. 
de-epithelialized corium-fat flaps), acellular dermis, or synthetic 
mesh are available and of equivalent value (AGO+). Volume defi-
cits and scars can be corrected using lipotransfer both after breast 
preservation and after mastectomy with reconstruction (LoE 2a/B/
AGO+). Numerous studies confirming the oncological safety of 
these approaches have been published in the meantime [98].
Neoadjuvant Chemotherapy
Survival rates are similar after primary systemic (‘preoperative’, 
‘neoadjuvant’) chemotherapy (NACT) and adjuvant therapy [99]. 
pCR defined as ypT0 ypN0 or ypT0/is ypN0 is associated with im-
proved survival [100, 101]. NACT remains the preferred therapeu-
tic option in patients who have an indication for adjuvant chemo-
therapy (LoE 1/B/AGO++). A recent Early Breast Cancer Trialists’ 
Collaborative Group (EBCTCG) meta-analysis of NACT trials 
with a follow-up of 15 years detected an increased rate of breast 
conservation with equal DFS and OS (compared to adjuvant ther-
apy). The increased rate of local recurrence cannot be attributed to 
NACT, but to different rates of recurrence after BCS versus mas-
tectomy [102]. Modern regimens are considered to be more effi-
cient (higher pCR) and to be safe for patients (improved surgical 
and radiotherapeutical approaches). NACT allows response-
guided therapies and novel post-neoadjuvant therapies in low or 
non-responding tumors. Dose-dense therapy regimens should be 
preferred (AGO++). In particular, in patient subgroups among 
whom a pCR is strongly associated with improved survival such as 
in TNBC, HER2-positive, and luminal B-like (HR-positive/HER2-
negative/G3, high Ki-67) cancer, NACT (plus targeted therapy) 
should be the preferred therapeutic approach (AGO++). In pa-
tients with TNBC (regardless of germline BRCA1/2 mutation sta-
tus), a platinum-containing regimen may be considered (LoE 2b/B/
AGO+) based on data from phase II randomized trials (e.g., Gepar-
Sixto, Cancer and Leukemia Group B (CALGB) 40603) [103]. The 
addition of carboplatin was not only associated with an increased 
pCR rate in both neoadjuvant trials but also resulted in a signifi-
cant improvement in GeparSixto with a DFS rate of 85.8% (with 
carboplatin) versus 76.1% without carboplatin (HR 0.56; p = 
0.0350) and a clinically meaningful albeit statistically not signifi-
cant improvement in DFS (absolute 5%) in the CALGB 40603 
study. Furthermore, the results of the GeparSepto trial suggest par-
ticular benefit from using nanoparticle albumin-bound (nab)-pa-
clitaxel 125 mg/m2 weekly instead of paclitaxel for patients with 
TNBC, which was not observed in the ETNA trial (LoE 2a/B/
AGO+/–) [104–107].
For HER2-positive patients, HER2-directed therapy is standard 
as part of neoadjuvant therapy. Given the significant increase in 
pCR rates and the trend for improved PFS observed in the neoad-
juvant NeoSphere trial with the addition of pertuzumab to trastu-
zumab, dual blockade is highly recommended in patients at high 
risk for recurrence [108–111] (LoE 2b/B/AGO++).
In patients with N+ or HR–/HER2/neu+ tumors, completion of 
combined therapy with trastuzumab and pertuzumab after surgery 
for a total of 52 weeks can be considered (LoE 2b/B/AGO+). With 
respect to endocrine neoadjuvant therapy, in exceptional situa-
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tions, endocrine treatment with gonadotropin-releasing hormone 
(GnRH) analogues plus an AI may be considered for premenopau-
sal women (LoE 1b/C/AGO+/–). Response-guided treatment has 
been shown to be beneficial within the GeparTrio trial. Conse-
quently, in the case of response after 2 cycles of DAC (docetaxel, 
adriamycin, cyclophosphamide) in HR-positive breast cancer, a 
total of 8 instead of 6 cycles of DAC may be considered to be ap-
propriate (LoE 2b/C/AGO+). In the case of no response after 2 cy-
cles of DAC, continuation of NACT with a non-cross-resistant 
regimen (LoE 2b/B/AGO+) such as 4 × vinorelbine/capecitabine 
(LoE 1b/B/AGO+) may be beneficial [112]. This can be an option 
in individual cases but cannot be considered as a routine approach. 
Post-neoadjuvant concepts are currently being investigated in clin-
ical trials, and trial participation is recommended if possible, par-
ticularly in the case of no pCR. Given the positive results of the 
CREATE-X study, further chemotherapy in the case of no pCR can 
be considered in high-risk cases (capecitabine in TNBC) (LoE 
2b/B/AGO+) [113]. Novel predictive factors, such as tumor-infil-
trating lymphocytes (LoE I/B/AGO+) or PIK3CA mutation in the 
tumor (LoE II/B/AGO+/–), are promising tools but currently not 
recommended in the routine clinical setting [114–117]. Patients 
with germline BRCA mutations have a higher probability to 
achieve a pCR [80]. The indications for mastectomy after NACT 
remain unchanged: positive margins after repeated excisions (LoE 
3b/C/AGO++), lack of feasibility of radiotherapy (LoE 5/D/
AGO++), and presence of inflammatory breast cancer (with no 
more than clinical complete response, LoE 2b/C/AGO+). In in-
flammatory breast cancer with pCR after NACT, BCT may be dis-
cussed with the patient. Furthermore, large tumors (cT4a–c) at 
first diagnosis represent only a relative indication for mastectomy 
after NACT (LoE 2b/B/AGO+/–). In the case of nodal involve-
ment, biopsy and clip marking of the positive nodes is recom-
mended if possible (LoE 5/D/AGO+). The SLN procedure is rec-
ommended preferably after neoadjuvant therapy in the case of cN0 
(LoE 2b/B/AGO+) (see also the section on surgery) [118–121]. De-
layed initiation of NACT for thorough diagnosis (imaging and/or 
molecular pathology) is not correlated with a negative outcome 
(LoE 2b/B122). Surgery after NACT should be planned no later 
than 2–4 weeks after the last chemotherapy cycle, after patients 
have recovered from hematological toxicities (2b/B/AGO++) 
[122–124].
Adjuvant Endocrine Therapy
Endocrine therapy still remains one of the most effective treat-
ment options in all settings of breast cancer. In the adjuvant situa-
tion, endocrine therapy is indicated in all patients with HR-positive 
breast cancer, as well as those with low HR-positive cancer (˰1–
9%, so-called ‘questionably sensitive’ cases; LoE 1/GR A/AGO++). 
If chemotherapy is indicated, endocrine therapy starts in sequence 
after cytotoxic therapy. At present, in the adjuvant setting, we dis-
tinguish between  ‘initial therapy’ (years 0–5) and ‘extended adju-
vant therapy’ (EAT, years 6–15; AGO++). Treatment duration of 5 
years remains the standard of care. EAT might be indicated in pa-
tients with increased risk of relapse based on the individual risk/
benefit ratio. Data from the EBCTCG estimates the risk of relapse 
after termination of endocrine adjuvant therapy at 5 years [125]. In 
premenopausal and perimenopausal patients, treatment with ta-
moxifen is indicated for 5–10 years (LoE 1a/GR A/AGO++). In ac-
cordance with data from the ATLAS and aTTom trials, tamoxifen 
therapy can be extended for up to 10 years [126]. If the patient is 
confirmed to be postmenopausal within the first 5 years, according 
to the data from the MA.17 study, endocrine therapy can be con-
tinued after 5 years of tamoxifen with 2.5–5 years of letrozole (LoE 
1b/GR B/AGO+) [127].
If chemotherapy was indicated as part of the (neo-)adjuvant set-
ting and ovarian function has recovered within the first 8 months 
afterwards, treatment with a GnRH analogue plus tamoxifen (LoE 
1b/GR B/AGO+) or with the AI exemestane for 5 years can be con-
sidered on an individual basis (LoE 1b/GR B/AGO+/–). In patients 
under the age of 35 years, in accordance with the full publication of 
the SOFT study, a combination of tamoxifen with a GnRH ana-
logue should be recommended, due to the significant benefit rela-
tive to OS (LoE 1b/GR B/AGO++) [128]. In women with endo-
crine-sensitive breast cancer without adjuvant chemotherapy and 
preserved ovarian function, the outcome of endocrine therapy with 
tamoxifen alone is highly favorable (LoE 1b/GR B/AGO++). The 
effect of additional ovarian downregulation with a GnRH agonist 
(GnRHa) is limited for tamoxifen + GnRHa (LoE 1b/GR B/
AGO+/–) or AIs + GnRHa (LoE 1b/GR B/AGO+/–). However, in-
creased side effects may impair compliance when GnRHa are 
added [129]. Tamoxifen alone still remains the standard of care.
It should be stated that GnRHa monotherapy might be indi-
cated in case of contraindication for either tamoxifen or aromatase 
inhibition compared to no endocrine therapy at all (LoE 1a/GR B/
AGO+).
In postmenopausal women, various options of the initial endo-
crine therapy (years 0–5) can be considered and there has been 
extensive discussion about the use of tamoxifen in comparison 
with an AI or sequential use of tamoxifen and an AI. Two meta-
analyses have been published during the last year and both suggest 
that AIs should be preferred to tamoxifen [130, 131]. In the 
EBCTCG meta-analysis, 5 years of treatment with an AI led not 
only to an improved 10-year breast cancer mortality rate in com-
parison with 5 years of tamoxifen but also to a reduced rate of re-
currences. Sequential treatment with tamoxifen followed by an AI 
was also superior with regard to mortality, so that in postmeno-
pausal patients either an AI or sequential treatment with tamox-
ifen followed by AI, or vice versa, should be used (LoE 1a/GR A/
AGO++). The 5-year AI therapy is preferable, particularly in pa-
tients with lobular cancer or with a high risk of recurrence, mostly 
if adjuvant chemotherapy was indicated. In summary, based on 
the EBCTCG publication in 2015, the most important impact on 
outcome was demonstrated when AIs were included for 3 years in 
the adjuvant setting. In postmenopausal women with low risk of 
recurrence, tamoxifen therapy upfront is still an option (LoE 1a/
GR A/AGO+).
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The issue of whether EAT should be recommended for recur-
rence-free patients after initial adjuvant therapy for 5 years is com-
plex. There are still no validated biomarkers identifying patients 
who are at increased risk of late relapse.
After 2–5 years of tamoxifen therapy in patients with higher 
risk, extended therapy with 5 years of tamoxifen can be adminis-
tered on the basis of the ATLAS study (LoE 1a/GR A/AGO++), or 
2.5–5 years of AI treatment in accordance with the MA 17 study 
(LoE 1a/GR B/AGO++) [132, 133].
The data on prolonging upfront therapy with AIs beyond a total 
of 5 years are currently heterogeneous. While 2 studies have shown 
a benefit (MA.17R: 5 years of AI after 5 years of AI, with or without 
prior therapy with tamoxifen; LATER: 5 years of AI after 4 years of 
endocrine therapy, 11.7% were pretreated with AI and 36.9% with 
tamoxifen followed by AI) [134, 135]. The recent publication of the 
IDEAL trial [136] and the DATA trial [137] failed to demonstrate 
the range of benefit that was shown in the MA.17 trial. Thus, in 
both trials (IDEAL, DATA), postmenopausal women received an 
AI as part of their initial adjuvant therapy. In summary, the indica-
tion for EAT using an AI after 2–5 years of tamoxifen is based on 
the risk of recurrence, the tolerability of the initial therapy, good 
bone health, and younger age. This needs to be discussed on an in-
dividual basis.
Three studies presented at the last San Antonio Breast Cancer 
Symposium were negative for the overall groups (DATA, IDEAL, 
and National Surgical Adjuvant Breast and Bowel Project (NSABP) 
B-42). However, since subgroups can possibly benefit, extension of 
endocrine therapy with an AI should be offered after initial AI-
containing therapy in patients who are at higher risk and have so 
far tolerated the AI well – e.g., those with good bone health, 
younger age, high risk according to immunohistochemical charac-
teristics, and positive nodal status (LoE 1b/GR B/AGO+). How-
ever, there is as yet no evidence of a significant effect on OS. In pa-
tients who are at low individual risk and/or have poor tolerance for 
the AI, AI therapy should not be continued beyond 5 years (LoE 
1b/GR B/AGO–).
Adjuvant Cytotoxic and Targeted Therapy
If adjuvant chemotherapy is indicated, neoadjuvant therapy 
should always be considered (AGO++). In adjuvant therapy, sys-
temic treatment encompassing 6 cycles of FEC (5-fluorouracil, epi-
rubicin, cyclophosphamide) is no longer recommended.
Standard adjuvant chemotherapy consists of combination regi-
mens based on anthracyclines and taxanes in patients with HER2-
negative tumors (LoE 1a/A/AGO++). Recommended conventional 
regimens include 4 × EC/AC (epirubicin, cyclophosphamide or 
doxorubicin, cyclophosphamide), followed by 12 × paclitaxel 
(weekly, q7d) (LoE 2b/B/AGO++). The benefit of this regimen has 
recently been confirmed in the 10-year follow-up data from E1199 
[138]. The study population was enriched with patients carrying 
high-risk features (46% premenopausal, 88% with involved lymph 
nodes). There were significant advantages for paclitaxel weekly re-
garding DFS and OS (DFS p < 0.001, OS p = 0.07). Of particular 
interest was the subgroup with TNBC: After 4 cycles of AC, pacli-
taxel weekly showed a significant OS benefit in comparison with 
3-weekly paclitaxel (HR 0.69, 95% CI 0.50–0.94).
In patients with cardiac comorbidities, treatment with docetaxel 
and cyclophosphamide might be used as an alternative (LoE 1b/B/
AGO+). The recently presented results of the Plan B trial con-
firmed an equivalent efficacy for 6 cycles of docetaxel and cyclo-
phosphamide compared with 4 × EC followed by 4 × docetaxel 
(LoE 1b/B/AGO+). In individual cases, treatments using paclitaxel 
mono weekly (LoE 1b/B/AGO+/–) or CMF (cyclophosphamide, 
methotrexate, fluorouracil) (LoE 1a/A/AGO+/–) may also be con-
sidered [139, 140].
Dose-dense chemotherapy is recommended to be used in high-
risk patients independent of tumor burden (LoE 1a/A/AGO++). 
The EBCTCG meta-analysis showed a significant benefit in DFS 
and breast cancer mortality for dose-dense chemotherapy com-
pared with standard dose regimens [141].
In case of 4 or more affected lymph nodes, dose-dense and 
dose-escalated treatment with epirubicin (150 mg/m2) followed by 
paclitaxel (225 mg/m2) followed by cyclophosphamide (2,500 mg/
m2), q14d, should be considered instead of standard 3-weekly regi-
mens (LoE 1b/A/AGO++) [142]. At present, platinum cannot be 
recommended in the adjuvant setting due to a lack of data and 
should be considered only in individual cases (LoE 5/D/AGO+). 
This is in contrast to the recommendations in the neoadjuvant set-
ting (see above).
In HER2-positive disease, an anti-HER2-directed treatment 
with trastuzumab is standard (LoE 1a/A/AGO++). In case of a pos-
itive nodal status and/or HR negativity, the application of a dual 
blockade consisting of trastuzumab and pertuzumab is recom-
mended according to the data of the APHINITY trial (node posi-
tive: HR 0.77, 95% CI, 0.62–0.96, p = 0.02; HR negative: HR 0.76, 
95% CI 0.56–1.04, p = 0.0847) (LoE 1b/B/AGO+) [143].
Trastuzumab with or without pertuzumab is recommended si-
multaneously in combination with a taxane (LoE 1b/A/AGO++). 
The optimal duration is 1 year (LoE 1b/A/AGO++) [144, 145].
Trastuzumab subcutaneously (s.c.) has the same efficacy as the 
intravenous (i.v.) formulation and can be used without concerns 
(LoE 1b/B/AGO++) [146, 147].
Alternative anthracycline-free combination partners for trastu-
zumab are docetaxel and carboplatin (LoE 1b/A/AGO+) or, in indi-
vidual cases, e.g. in patients with tumors <2 cm and negative nodal 
status, treatment with 12 × paclitaxel q7d (LoE 2b/B/AGO+) [148].
After 1 year of trastuzumab, an extension of the adjuvant anti-
HER2 treatment with 1 year of neratinib can be recommended after 
individual risk/benefit discussion with the patient. In HR-positive 
disease, the ExteNET trial showed a significantly increased DFS of 
91.2% versus 86.8% (HR 0.60, 95% CI 0.43–0.83); however, diarrhea 
G3 occurred in 40% of the patients (LoE 2b/B/AGO+/) [202].
Biosimilar trastuzumab has become a reality for European on-
cologists. Several studies are still ongoing, but 2 trastuzumab bio-
similars are already approved by the European Medicines Agency 
(EMA). These compounds can be used in daily practice if they have 
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passed a stringent development and validation process required by 
the EMA, the US Food and Drug Administration (FDA), or other 
similarly strict authorities [149–152].
Adjuvant Radiotherapy
Adjuvant radiotherapy is an essential part of the primary treat-
ment in early breast cancer and contributes substantially to disease 
control. Experts from the field of gynecology and radiation oncol-
ogy representing their corresponding guideline committees, the 
AGO and the Deutsche Gesellschaft für Radioonkologie (German 
Society of Radiation Oncology/DEGRO), developed the joint AGO 
recommendations for adjuvant radiotherapy based on an intense 
consensus discussion. For technical details on radiotherapy, we 
agreed to refer to the corresponding updated DEGRO practical 
guidelines [153, 154].
The AGO and DEGRO experts agreed with regard to future de-
velopments in radiotherapy towards a risk-adapted approach: In 
many situations, radiotherapy will be optimized, reduced or even 
spared. On the other hand, use of radiotherapy may be established 
or expanded for indications that were not considered before.
The optimal type of breast irradiation after BCT is still a matter 
of debate. After the convincing data of the START A and START B 
trials as well as the Canadian trial, hypofractionated irradiation 
consisting of 15 or 16 fractions to total doses of 40–42 Gy is widely 
accepted as the new standard of breast radiotherapy according to 
the German S3 guideline (www.awmf.org/leitlinien/detail/ll/032-
045OL.html), international guidelines [155–158], and common 
practice [159–161], and was recently confirmed by an updated 
Cochrane analysis. We agreed to underscore hypofractionated ir-
radiation (15–16 fractions) as the preferred type of irradiation and 
to leave conventionally fractionated radiotherapy as an alternative 
method. In patients <50 years of age and in high-risk patients aged 
˰50 years, an additional boost of 10–16 Gy to the tumor bed is rec-
ommended, although the improvement in local control is quite 
small in patients older than 40 years [162].
If radiotherapy of the regional lymph nodes is included, con-
ventionally fractionated radiotherapy (25–28 fractions) is still 
recommended.
In patients with a life expectancy below 10 years, omission of 
radiotherapy is an option for patients with low risk of recurrence 
such as pT1 pN0 R0 HR-positive/HER2-negative if adjuvant endo-
crine treatment is performed (LoE 1a/B/AGO+) [163]. There is no 
influence on OS, and side effects can be avoided. The AGO and the 
DEGRO agree that in elderly low-risk patients accelerated partial 
breast irradiation (APBI) can be delivered as the sole radiotherapy 
modality either during surgery (intraoperative radiation therapy 
(IORT) 50 kV, intraoperative electron radiation therapy (IOERT)) 
or after surgery using brachytherapy (patients >50 years, only for 
pT1 pN0 R0 G1–2, HR-positive, non-lobular, no extensive DCIS).
Irradiation of the chest wall and regional lymphatics (post-mas-
tectomy radiotherapy, PMRT) is indicated if more than 3 axillary 
lymph nodes were tumor-infiltrated [164]. With regard to patients 
with 1–3 infiltrated nodes (pN1), we recommend PMRT for any 
number of positive lymph nodes in all high-risk patients and in se-
lected patients with intermediate risk. However, retrospective anal-
yses suggest that in low-risk patients with less than 4 tumor-infil-
trated lymph nodes (pN1a), in some cases, no real benefit can be 
expected, e.g. in those with ER-positive, HER2-negative, well-dif-
ferentiated (G1) pT1 tumors. On the other hand, in patients with 
high-risk features, e.g. with high axillary tumor load (i.e. >25% of 
removed lymph nodes are positive), undifferentiated (G3) tumors, 
triple-negative immunohistochemistry, lymphovascular invasion, 
or in younger patients with ER-negative tumors (<45 years) or 
HER2-positive tumors (<40 years), several analyses show an ele-
vated risk of recurrence and consequently an indication for PMRT.
Based on retrospective data, omission of PMRT was discussed in 
patients with pN1 tumors if 3 of 4 low-risk criteria are fulfilled (ER-
positive, G1, HER2-negative, pT1) [165, 166]; on the other hand, in 
patients with high-risk criteria such as vessel invasion, HER2 posi-
tivity, high grade (G3), high proportion of positive lymph nodes 
(>25%), and young age (<40 or <45 years if ER-negative or medial 
tumor location), a benefit from PMRT is expected [166, 167]. How-
ever, for some patients, individual discussion will be required.
Radiotherapy of the medial supra-/infraclavicular and internal 
mammary chain lymph nodes consistently improved the DFS and 
distant metastasis-free survival in 2 large randomized controlled tri-
als [168, 169] and in a Danish population-based study [170], result-
ing in a small but statistically significant OS benefit in the meta-
analyses of these trials [171]. The majority of patients in these trials 
had either node-positive breast cancer or centrally or medially lo-
cated node-negative breast cancer. The AGO and DEGRO experts 
recommend lymph node irradiation of the internal mammary chain, 
starting in high-risk patients with pN1a (G2–3, HR-negative, post-
menopausal: central/medial location, <45 years also lateral location) 
or more positive lymph nodes. For patients who receive trastu-
zumab, radiotherapy of the internal mammary chain lymph nodes 
should only be performed with special emphasis on heart dose.
Currently, prospective evidence regarding PMRT following 
NACT and individualization based on treatment response is scarce 
until results from NSABP B-51 are available. PMRT is therefore 
recommended for all patients with initially locally advanced tu-
mors and for initially node-positive patients without pCR. Indi-
vidualization can be performed in patients with cT1/2 cN+ tumors 
showing a pCR (ypT0/ypN0) after NACT based on the presence of 
risk factors (e.g. G2–3, HR-negative, premenopausal, medial/cen-
tral localization).
Gynecological Issues in Breast Cancer Patients/ 
Contraception
Treatment of Menopausal Symptoms
Classical hormonal replacement therapy to alleviate menopausal 
symptoms is not indicated in breast cancer patients, particularly in 
ER-positive disease (LoE 1b/B/AGO–), but might be considered in 
individual cases and after failure of other non-hormonal treatments 
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(LoE 3b/B/AGO+/–). Tibolone is contraindicated (LoE 1b/A/
AGO–/–), while topical vaginal application of low-dose estriol may 
be used for urogenital symptoms (LoE 4/D/AGO+/–). Menopausal 
symptoms such as hot flushes, night sweats, or sleep disturbances 
may be treated with various non-hormonal remedies, e.g. serotonin 
reuptake inhibitors (i.e. venlafaxine (LoE 1a/A/AGO+)), which 
carry the potential to reduce hot flushes by about 60%.
The majority of studies on the efficacy of herbal treatments for 
menopausal symptoms – mostly hot flushes – were not conducted 
in women with breast cancer, and many were of short duration. 
Increased pharmacovigilance for herbal medicines is required, e.g. 
initiatives to stimulate reporting of suspected adverse reactions. 
Neither flax seed nor black cohosh (Cimicifuga racemosa) nor St. 
John’s wort nor ginseng root nor soy could improve menopausal 
symptoms.
Physical exercise and cognitive behavioral therapy have positive 
effects on menopausal symptoms and, to a lesser degree, on the sex-
uality and physical functioning of patients with breast cancer expe-
riencing treatment-induced menopause (LoE 1b/B/AGO+). Mind-
body medicine (MBM; relaxation training, yoga, hypnosis) is re-
ported to result in a moderate and even significant improvement in 
hot flushes scores, joint pain, fatigue, sleep, mood, and relaxation 
(LoE 1b/B/AGO+/+). These effects are seen even after longer peri-
ods of application and some months after stopping MBM. There is 
contradictory data about the effect of acupuncture on hot flushes, 
but in a review comparing 12 randomized controlled trials, the au-
thors concluded that acupuncture had no significant effect on re-
ducing hot flushes (LoE 1a/A/AGO+/–) [172]. Acupuncture might 
be used to treat AI-induced joint pain (LoE 1b/B/AGO+) [173].
Fertility Preservation
Counseling on fertility preservation is suggested in all patients 
who wish to retain their fertility (LoE 4/C/AGO+). Application of 
GnRH analogues given 2 weeks prior to chemotherapy has been 
shown to give a higher rate of recovery of ovarian function after 2 
years (LoE 1a/B/AGO+) and might have a moderate effect on fer-
tility preservation (LoE 2a/B/AGO+/–) [174]. No negative effect 
with regard to prognosis could be observed independent of the HR 
status of the primary tumor.
Menstrual history is reliable only in women under 45 years of 
age. A more precise evaluation of the ovarian reserve (particularly 
in perimenopausal patients) may be obtained by the measurement 
of follicle-stimulating hormone (FSH) and estradiol levels in the 
peripheral blood. Low anti-Muellerian hormone levels seem to be 
indicative of reduced ovarian reserve and chemotherapy-related 
amenorrhea in chemotherapy-treated breast cancer patients [175]. 
An antral follicle count, defined as the sum of the follicle diameters 
of all follicles of 10 mm in both ovaries, can be easily performed at 
little extra cost.
Contraception
All patients of childbearing potential must be counseled about 
adequate contraception prior to systemic therapy since cytotoxic 
treatment, including endocrine therapy, by itself does not confer 
reliable protection against pregnancy. The majority of contracep-
tive measures have not been tested in women after breast cancer 
and hormone-free methods are the first choice for patients with 
breast cancer.
Sexual Health
Sexual complaints are common in breast cancer patients and 
should be assessed. They include sexual desire disorder/decreased 
libido (23–64% of patients), arousal or lubrication concerns (20–
48% of patients), and dyspareunia (35–38% of patients). Screening 
tools may help physicians to address sexual health issues (LoE 4/C/
AGO+).
Non-hormonal lubricants and moisturizers are the primary 
treatment for vaginal dryness. Silicone-based products may last 
longer than water-based or glycerin-based products (LoE 1b/B/
AGO+). Microablative fractionated laser or vaginal YAG/erbium 
laser (erbium-doped yttrium aluminum garnet laser) may be an 
option for some patients to alleviate genital atrophy (LoE 2b/B/
AGO+/–) [176].
Complementary Therapy – Survivorship
‘Integrative oncology is a patient-centered, evidence-informed 
field of cancer care that utilizes mind and body practices, natural 
products, and/or lifestyle modifications from different traditions 
alongside conventional cancer treatments. Integrative oncology 
aims to optimize health, quality of life, and clinical outcomes 
across the cancer care continuum and to empower people to pre-
vent cancer and become active participants before, during, and be-
yond cancer treatment’ [177].
In 2018, the AGO guidelines for ‘Complementary Therapy – 
Hormonal Treatment and Alternatives in Breast Cancer Survivors 
– Survivorship’ did not change substantially, since the data pre-
sented in 2017 altered mostly evidence levels (LoE) but not the 
AGO recommendations.
Some small studies suggested that massage with or without 
aroma therapy may help relieve short- or medium-term pain and 
anxiety in people with cancer. However, the quality of evidence 
was very low and the results were not consistent. Acupuncture 
seems to significantly ameliorate menopause symptoms (LoE 1b/B/
AGO+) without significant effect on the frequency and the severity 
of hot flushes (LoE 1b/B/AGO+/–) as a recent meta-analysis shows 
[178]. Also acupuncture can be recommended to reduce AI-related 
joint symptoms (LoE 1a/B/AGO+) [179]. A randomized blinded 
sham- and waitlist-controlled trial with 226 patients was presented 
by Dawn Hershman at the San Antonio Breast Cancer Symposium 
2017.
Evidence is growing that acupressure can be considered to ame-
liorate cancer-related fatigue (LoE 1b/B/AGO+) and insomnia 
[180, 181]. Patients can be taught to apply the acupressure to 
themselves.
A meta-analysis of 10 studies (n = 1,709) revealed evidence for 
the short-term effectiveness and safety of mindfulness-based inter-
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ventions in women with breast cancer during and after adjuvant 
treatment. Compared to usual care, significant post-intervention 
effects were found for health-related quality of life, fatigue, sleep, 
stress, anxiety, and depression (LoE 1a/A/AGO+) [182].
Exercise leads to several positive outcomes in oncology. A re-
cent randomized controlled trial showed that exercise intervention 
significantly decreased sleep problems in breast cancer patients 
going through radiotherapy (LoE 1a/A/AGO++) [183].
A Cochrane review including 24 studies with a total of 2,166 
participants supports the recommendation of yoga as a supportive 
intervention for improving health-related quality of life and reduc-
ing fatigue and sleep disturbances as well as for reducing depres-
sion, anxiety, and fatigue, when compared with psychosocial/edu-
cational interventions (LoE 1b/A/AGO+) [184].
A well-designed non-inferiority trial demonstrated clinically 
meaningful improvements in insomnia after cognitive behavioral 
therapy and tai chi, a movement meditation. Tai chi was found to 
be statistically non-inferior to CBT-I, the gold standard for behav-
ioral treatment of insomnia (LoE 2a/B/AGO+/–) [185].
Breast Cancer: Special Situations
Breast cancer in pregnancy should be treated as close as possible 
to the guidelines in non-pregnant patients [186]. Nevertheless, 
staging and systemic therapy do have some restrictions due to po-
tential fetal harm. Recent cohort studies indicate that whole-body 
MRI without a contrast agent provides valuable staging informa-
tion and may be considered in individual high-risk cases (AGO+/–) 
[187]. Surgery should be performed as in non-pregnant women 
and SLNB is feasible. Regarding systemic therapy, anthracyclines 
and taxanes are safe to be used in pregnancy. Platinum salts may be 
considered (AGO+/–) based on data mostly from gynecological tu-
mors [188]. Radiotherapy, endocrine therapy, and monoclonal an-
tibodies should be avoided during pregnancy.
In inflammatory breast cancer (IBC), mastectomy is standard of 
care (AGO+). In a large IBC cohort from the Surveillance, Epide-
miology and End Results (SEER) data base (n = 3,374), no statisti-
cally significant difference regarding breast cancer-specific survival 
or OS was found between the different types of breast surgery such 
as breast-conserving surgery, contralateral prophylactic mastec-
tomy, breast reconstruction, or standard unilateral mastectomy 
[189].
In axillary metastases of occult breast cancer (axillary CUP), ra-
diotherapy of the ipsilateral breast improves outcome (AGO+). In 
a large case series from the National Cancer Database, axillary me-
tastases with an occult breast cancer were very rare (0.09%). Treat-
ment with radiotherapy and AD was an independent predictor of 
OS in multivariable analysis (HR 0.509, 95% CI 0.321–0.808, p = 
0.004) [190].
Metaplastic breast cancer is a rare subtype with an incidence of 
0.2–5% of all breast cancers [191]. These tumors are characterized 
by an epithelial and mesenchymal differentiation with 2–3 differ-
ent components and a high proliferation rate. These different com-
ponents are the basis for the classification according to the World 
Health Organization (WHO) criteria [192]. More than 90% of 
metaplastic breast cancers are negative for ER, PR, and HER2 but, 
in contrast, there is an overexpression of HER1 and cytokeratin 5/6 
(CK5/6) (stem cell and BRCA-like) [193] and the molecular profile 
is more basal-like [194]. The clinical features show large tumors at 
diagnosis (>5 cm), frequent hematogenous metastases and nodal 
involvement in about 20% of all cases. Imaging and gaining histol-
ogy for diagnosis should be performed according to standard 
(AGO++). Due to the high frequency of hematogenous metastases, 
staging should encompass chest and abdominal CT (AGO++). Sur-
gical treatment can be performed according to standard (including 
SLNB, AGO+), but mastectomy is more often necessary due to 
more advanced tumor stage and the goal of tumor-free resection 
margins of more than 3 cm [195–197]. Adjuvant treatment consists 
of chemotherapy (even tumors are more chemoresistant), endo-
crine therapy (only in HR-positive tumors) [197], and standard ra-
diotherapy [198].
Conclusion
These guidelines offer the freshest recommendations in the di-
agnosis and treatment of early breast cancer. Meanwhile, we have 
reached a rather high level with regard to long-term prognosis, ex-
hibiting low rates of recurrences and deaths even after 10 and 15 
years. The trend of these recommendations shows increasing opti-
mization and individualization by reducing treatment aggressive-
ness if possible (e.g. less axillary surgery, hypofractionation of ra-
diotherapy in BCT) and escalating some specific therapies modali-
ties (e.g. irradiation of lymph node areas, dose-dense chemother-
apy). Thus, following these concepts, early breast cancer is a 
curable disease. Having accepted some toxicity, we have to put our 
efforts into the reduction of side effects now.
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